A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.

Humans Female Breast Neoplasms / diagnosis BRCA1 Protein BRCA2 Protein Biomarkers, Tumor / genetics Carcinoma / genetics
Biomarkers Breast cancer Companion diagnostic Metastasis PD-L1 Tumor mutation burden

Journal

Clinics in laboratory medicine
ISSN: 1557-9832
Titre abrégé: Clin Lab Med
Pays: United States
ID NLM: 8100174

Informations de publication

Date de publication:
06 2023
Historique:
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: ppublish

Résumé

Predictive biomarker testing on metastatic breast cancer is essential for determining patient eligibility for targeted therapeutics. The National Comprehensive Cancer Network currently recommends assessment of specific biomarkers on metastatic tumor subtypes, including hormone receptors, HER2, and BRCA1/2 mutations, on all newly metastatic breast cancers subtypes; programmed death-ligand 1 on metastatic triple-negative carcinomas; and PIK3CA mutation status on estrogen receptor-positive carcinomas. In select circumstances mismatch repair protein deficiency and/or microsatellite insufficiency, tumor mutation burden, and NTRK translocation status are also testing options. Novel biomarker testing, such as detecting PIK3CA mutations in circulating tumor DNA, is expanding in this rapidly evolving arena.

Identifiants

DOI: 10.1016/j.cll.2023.03.004 PMID: 37169447
pubmed: 37169447
pii: S0272-2712(23)00024-0
doi: 10.1016/j.cll.2023.03.004
pii:
doi:

Substances chimiques

BRCA1 protein, human 0
BRCA1 Protein 0
BRCA2 protein, human 0
BRCA2 Protein 0
Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-321

Commentaires et corrections

Type : ReprintOf

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure G. Jagannathan: None; M.J. White: None; R.R. Xian: None; L.A. Emens: honoraria from AbbVie, Amgen, Celgene, Chugai, GCPR, Gilead, Gritstone, MedImmune, Peregrine, Shionogi, and Syndax; honoraria and travel support from AstraZeneca, Bayer, MacroGenics, Replimune, and Vaccinex; travel support from Bristol Myers Squibb, Genentech/Roche, and Novartis; potential future stock from Molecuvax; institutional support from AbbVie, Aduro Biotech, AstraZeneca, the Breast Cancer Research Foundation, Bristol Myers Squibb, Bolt Therapeutics, Compugen, Corvus, CyTomX, the US Department of Defense, EMD Serono, Genentech, Maxcyte, Merck, the National Cancer Institute, the NSABP Foundation, SU2C, Silverback, Roche, the Translational Breast Cancer Research Consortium, Takeda, Tempest, and HeritX; royalties from Aduro Biotech; A. Cimino-Mathews: Research grants to institution from Bristol-Myers Squibb; consultancy/honoraria to self from Bristol-Myers Squibb and Roche.

Auteurs

Geetha Jagannathan (G)

Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA.

Marissa J White (MJ)

Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA.

Rena R Xian (RR)

Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA; Department of Oncology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA.

Leisha A Emens (LA)

Department of Oncology, UPMC Hillman Cancer Center/Magee Women's Hospital, 5117 Centre Avenue, Room 1.46e, Pittsburgh, PA 15213, USA.

Ashley Cimino-Mathews (A)

Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA; Department of Oncology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA. Electronic address: acimino1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A New Landscape of Testing and Therapeutics in...
Recherchemedicale.com › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › A New Landscape of Testing and Therapeutics in...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine BRCA1 › A New Landscape of Testing and Therapeutics in...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéine BRCA2 › A New Landscape of Testing and Therapeutics in...
Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › A New Landscape of Testing and Therapeutics in...
Recherchemedicale.com › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › A New Landscape of Testing and Therapeutics in...